Evaluating Renal Benefits of Rivaroxaban Versus Vitamin K Antagonists in Atrial Fibrillation: A Systematic Review and Meta-analysis of Real-world Evidence

被引:0
|
作者
Dinh, Phong Phan [1 ,2 ]
Ho, Tri Huynh Quang [3 ]
Pham, Hung Manh [1 ,2 ,6 ]
Nguyen, Hai Hoang [4 ]
Ton, Minh That [5 ]
Tran, Giang Song [1 ]
Vu, Nga Quynh [6 ]
Pham, Hung Nhu
Cao, Son Luong [7 ]
Hoang, Sy Van [8 ,9 ]
机构
[1] Bach Mai Hosp, Vietnam Natl Heart Inst, Hanoi, Vietnam
[2] Hanoi Med Univ, Hanoi, Vietnam
[3] Heart Inst, Surg Intens Care Unit, Ho Chi Minh City, Vietnam
[4] Nhan Dan Gia Dinh Hosp, Ho Chi Minh City, Vietnam
[5] Tam Duc Heart Hosp, Ho Chi Minh City, Vietnam
[6] Hanoi Heart Hosp, Hanoi, Vietnam
[7] Univ Med Ctr Ho Chi Minh City, Dept Cardiol, Ho Chi Minh City, Vietnam
[8] Cho Ray Hosp, Cardiovasc Dept, Ho Chi Minh City, Vietnam
[9] Univ Med & Pharm Ho Chi Minh City, Ho Chi Minh City, Vietnam
关键词
Rivaroxaban; AF; acute kidney injury; renal failure; anticoagulant -related nephropathy; CHRONIC KIDNEY-DISEASE; CLINICAL-TRIALS; OUTCOMES; RISK; ANTICOAGULANTS; WARFARIN; DECLINE; INJURY;
D O I
10.15420/ecr.2024.07
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: AF is a global health concern, with systemic complications including renal dysfunction. This systematic review and meta-analysis compares the effects of rivaroxaban, a Factor Xa inhibitor, and vitamin K antagonists (VKAs) on renal outcomes in AF patients. Methods: The study protocol is registered in PROSPERO (ID: CRD42023462756). We systematically searched the PubMed, Embase and Cochrane Library databases from 1 January 2017 to 30 June 2023 for real-world studies comparing the effects of rivaroxaban and VKAs on renal outcomes in AF patients, including acute kidney injury, a >= 30% decrease in estimated glomerular filtration rate, doubling of serum creatinine and worsening renal function. Subgroup analyses targeted diabetes, pre-existing kidney disease, the elderly (age >= 65 years) and Asian populations. The risk of bias was assessed used the Robins-I tool. HRs and 95% CIs were synthesised through a random-effects model. Two sensitivity analyses were performed, using a fixed-effects model and excluding conference abstracts. Results: We identified 1,666 records. After screening, 14 studies comparing rivaroxaban and VKAs were included. Rivaroxaban exhibited superiority over VKAs in preventing: acute kidney injury (HR 0.68; 95% CI [0.61-0.77]; p<0.00001); a >= 30% decrease in estimated glomerular filtration rate (HR 0.71; 95% CI [0.60-0.84]; p<0.0001); doubling of serum creatinine (HR 0.50; 95% CI [0.36-0.70]; p<0.0001); and worsening renal function (HR 0.56; 95% CI [0.45-0.69]; p<0.00001). Subgroup and sensitivity analyses consistently confirmed rivaroxaban's favourable effects on renal outcomes in diabetes, pre-existing kidney disease, the elderly and Asian populations. Conclusion: Our findings support the preference of rivaroxaban over VKAs for renal outcomes in AF. The findings endorse rivaroxaban as the preferred anticoagulant to mitigate renal complications, offering clinicians valuable insights for tailored strategies.
引用
收藏
页数:12
相关论文
共 50 条
  • [21] Direct Oral Anticoagulants versus Vitamin K Antagonists in Cirrhotic Patients with Atrial Fibrillation: Update of Systematic Review and Meta-Analysis
    Tong Hu
    Yi-Han Li
    Wen-Qiang Han
    Kellina Maduray
    Tong-Shuai Chen
    Li Hao
    Jing-Quan Zhong
    American Journal of Cardiovascular Drugs, 2023, 23 : 683 - 694
  • [22] Direct Oral Anticoagulants versus Vitamin K Antagonists in Cirrhotic Patients with Atrial Fibrillation: Update of Systematic Review and Meta-Analysis
    Hu, Tong
    Li, Yi-Han
    Han, Wen-Qiang
    Maduray, Kellina
    Chen, Tong-Shuai
    Hao, Li
    Zhong, Jing-Quan
    AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS, 2023, 23 (06) : 683 - 694
  • [23] Direct Oral Anticoagulants Versus Vitamin K Antagonists in Patients Undergoing Cardioversion for Atrial Fibrillation: a Systematic Review and Meta-analysis
    Saurabh Gupta
    Kevin J. Um
    Arjun Pandey
    William F. McIntyre
    Marina Ivanova
    Yasamin Allahverdi
    Parisa Agahi
    Feny Pandya
    Ana Lopez
    Amrit Sachdeva
    Richard P. Whitlock
    Emilie P. Belley-Cote
    Cardiovascular Drugs and Therapy, 2019, 33 : 339 - 352
  • [24] META-ANALYSIS OF RISK OF STROKE AND THROMBO-EMBOLISM WITH RIVAROXABAN VERSUS VITAMIN K ANTAGONISTS IN ABLATION AND CARDIOVERSION OF ATRIAL FIBRILLATION
    Nairooz, Ramez S.
    Sardar, Partha
    Pino, Maria
    Amin, Hossam
    Sewani, Asif
    Maskoun, Waddah
    Paydak, Hakan
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2015, 65 (10) : A349 - A349
  • [25] Meta-analysis of risk of stroke and thrombo-embolism with rivaroxaban versus vitamin K antagonists in ablation and cardioversion of atrial fibrillation
    Nairooz, Ramez
    Sardar, Partha
    Pino, Maria
    Aronow, Wilbert S.
    Sewani, Asif
    Mukherjee, Debabrata
    Paydak, Hakan
    Maskoun, Waddah
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2015, 187 : 345 - 353
  • [26] RIVAROXABAN VS. DABIGATRAN OR WARFARIN IN REAL-WORLD OBSERVATIONAL STUDIES OF STROKE PREVENTION IN ATRIAL FIBRILLATION: SYSTEMATIC REVIEW AND META-ANALYSIS
    Bai, Ying
    Deng, Hai
    Shantsila, Alena
    Lip, Gregory Y. H.
    HEART, 2017, 103 : A36 - A37
  • [27] Real-world comparisons of reduced-dose non-vitamin K antagonist oral anticoagulants versus warfarin in atrial fibrillation: a systematic review and meta-analysis
    Wang, Xiaoping
    Fang, Lili
    Liu, Bin
    Zheng, Yongliang
    Zeng, Junquan
    HEART FAILURE REVIEWS, 2020, 25 (06) : 973 - 983
  • [28] Real-world comparisons of reduced-dose non-vitamin K antagonist oral anticoagulants versus warfarin in atrial fibrillation: a systematic review and meta-analysis
    Xiaoping Wang
    Lili Fang
    Bin Liu
    Yongliang Zheng
    Junquan Zeng
    Heart Failure Reviews, 2020, 25 : 973 - 983
  • [29] Real-World Use of Apixaban for Stroke Prevention in Atrial Fibrillation A Systematic Review and Meta-Analysis
    Proietti, Marco
    Romanazzi, Imma
    Romiti, Giulio Francesco
    Farcomeni, Alessio
    Lip, Gregory Y. H.
    STROKE, 2018, 49 (01) : 98 - +
  • [30] Real-world clinical evidence on rivaroxaban, dabigatran, and apixaban compared with vitamin K antagonists in patients with nonvalvular atrial fibrillation: a systematic literature review (vol 19, pg 27, 2019)
    Briere, J-B
    Bowrin, K.
    Coleman, C.
    Fauchier, L.
    Levy, P.
    Folkerts, K.
    Toumi, M.
    Taieb, V
    Millier, A.
    Wu, O.
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2019, 19 (04) : 503 - 503